GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (TSX:NVLN) » Definitions » Cash from Discontinued Operating Activities

Novelion Therapeutics (TSX:NVLN) Cash from Discontinued Operating Activities : C$0.0 Mil (TTM As of Mar. 2019)


View and export this data going back to 1988. Start your Free Trial

What is Novelion Therapeutics Cash from Discontinued Operating Activities?

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Novelion Therapeutics's Cash from Discontinued Operating Activities for the three months ended in Mar. 2019 was C$0.0 Mil. It means Novelion Therapeutics received C$0.0 Mil from discontinued investing activities. Novelion Therapeutics's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Mar. 2019 was C$0.0 Mil.


Novelion Therapeutics Cash from Discontinued Operating Activities Historical Data

The historical data trend for Novelion Therapeutics's Cash from Discontinued Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics Cash from Discontinued Operating Activities Chart

Novelion Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cash from Discontinued Operating Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novelion Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
Cash from Discontinued Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Novelion Therapeutics Cash from Discontinued Operating Activities Calculation

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novelion Therapeutics Cash from Discontinued Operating Activities Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's Cash from Discontinued Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


Novelion Therapeutics (TSX:NVLN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (TSX:NVLN) » Definitions » Cash from Discontinued Operating Activities
Traded in Other Exchanges
N/A
Address
c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.

Novelion Therapeutics (TSX:NVLN) Headlines

No Headlines